The Brazil CAR T-Cell Therapy market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Chimeric Antigen Receptor (CAR) T cell therapy is one type of cancer treatment, which helps to change patients’ T cells so they will attack cancer cells. Firstly, the CAR T cell ingrown in the laboratory, and it was given to patients by infusion. CAR T cells’ distinctive characteristic is to bind to an antigen on the cancer cells and kill them. CAR T cell therapy treatment is mostly used in blood cancer and some, among others. Recently, CAR T cell therapy has been preferred over radiation and chemotherapy.
CAR T cells become activated when targeted over antigen and bind to it to destroy the specific cells. The transfer of T cells is an anti-cancer therapeutic process that focuses virtually on any tumor-associated antigen.
The industry is being driven by rising government measures to enhance healthcare facilities and promote cancer-cell therapy research.
The government’s increased support in introducing better reimbursement schemes in favour of the poor people is also escalating the market demand. Furthermore, the implementation of procedures with advanced technologies and innovative treatment procedures with fewer side effects are expected to surge the market’s growth rate.
Major CAR T-Cell Therapy Market by Disease Indication
Based on disease indication, the market is segmented into Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Follicular Lymphoma and Others. The Multiple Myeloma sector is leading with the highest shares of the market and is estimated to continue the same growth in the coming years. Multiple myeloma segment has grown in the T cell therapy market. The new acute lymphocytic leukemia and Diffuse large B-cell lymphoma (DLBCL) segment is expected to grow in the coming decades.